Literature DB >> 21837588

[Is hyponatremia a prognostic marker of survival for lung cancer?].

C Petereit1, O Zaba, I Teber, C Grohé.   

Abstract

Hyponatremia is frequently observed on the basis of syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH) in patients suffering from lung cancer. This electrolyte imbalance is associated with higher mortality and morbidity. If hyponatremia influences survival of lung cancer remains controversial. In the current study we retrospectively analysed if survival is directly impacted by hyponatremia and evaluated if hyponatremia is a prognostic marker for lung cancer. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837588     DOI: 10.1055/s-0030-1256668

Source DB:  PubMed          Journal:  Pneumologie        ISSN: 0934-8387


  20 in total

1.  The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases.

Authors:  S Rinaldi; M Santoni; G Leoni; I Fiordoliva; G Marcantognini; T Meletani; G Armento; D Santini; T Newsom-Davis; M Tiberi; F Morgese; M Torniai; M Bower; Rossana Berardi
Journal:  Support Care Cancer       Date:  2018-11-08       Impact factor: 3.603

2.  Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.

Authors:  R Berardi; M Caramanti; I Fiordoliva; F Morgese; A Savini; S Rinaldi; M Torniai; M Tiberi; C Ferrini; M Castagnani; F Rovinelli; A Onofri; S Cascinu
Journal:  Support Care Cancer       Date:  2014-08-21       Impact factor: 3.603

3.  Tolvaptan corrects hyponatremia and relieves the burden of fluid/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases.

Authors:  Keiko Kai; Naoto Tominaga; Kenichiro Koitabashi; Daisuke Ichikawa; Yugo Shibagaki
Journal:  CEN Case Rep       Date:  2019-01-14

4.  Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients.

Authors:  R Berardi; M Caramanti; M Castagnani; S Guglielmi; F Marcucci; A Savini; F Morgese; S Rinaldi; C Ferrini; M Tiberi; M Torniai; F Rovinelli; I Fiordoliva; A Onofri; S Cascinu
Journal:  Support Care Cancer       Date:  2015-03-05       Impact factor: 3.603

5.  Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro.

Authors:  Giada Marroncini; Benedetta Fibbi; Alice Errico; Cecilia Grappone; Mario Maggi; Alessandro Peri
Journal:  Endocrine       Date:  2019-11-29       Impact factor: 3.633

6.  The Incidence of Hyponatraemia and Its Effect on the ECOG Performance Status among Lung Cancer Patients.

Authors:  Amitabha Sengupta; Sourindra Nath Banerjee; Nirendra Mohan Biswas; Debraj Jash; Kaushik Saha; Arnab Maji; Ankan Bandyopadhyaya; Sandip Agarwal
Journal:  J Clin Diagn Res       Date:  2013-08-01

Review 7.  Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials.

Authors:  Rossana Berardi; Matteo Santoni; Silvia Rinaldi; Emilia Nunzi; Alessia Smerilli; Miriam Caramanti; Francesca Morgese; Mariangela Torniai; Agnese Savini; Ilaria Fiordoliva; Azzurra Onofri; Mirco Pistelli; Augusto Taccaliti; Stefano Cascinu
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

8.  Prevalence of Hyponatremia in Palliative Care Patients.

Authors:  Shoba Nair; Thiophin Regina Mary; S D Tarey; Sudha Pauline Daniel; Jose Austine
Journal:  Indian J Palliat Care       Date:  2016 Jan-Mar

9.  A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.

Authors:  Claudia Petereit; Okan Zaba; Ishak Teber; Heike Lüders; Christian Grohé
Journal:  BMC Pulm Med       Date:  2013-08-29       Impact factor: 3.317

Review 10.  Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives.

Authors:  Bijin Thajudeen; Abdulla K Salahudeen
Journal:  Cancer Manag Res       Date:  2016-08-22       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.